
|Videos|December 16, 2017
The Role of Enzalutamide in HR+ Advanced Breast Cancer
Author(s)Denise Yardley, MD
Denise Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses the role of enzalutamide in hormone-receptor positive (HR+) advanced breast cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















